The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Natural History of Alkaptonuria
Open accessAbstract
BACKGROUND: Alkaptonuria, caused by mutations in the HGO gene and a deficiency of homogentisate 1,2-dioxygenase, results in an accumulation of homogentisic acid (HGA), ochronosis, and destruction of connective tissue. There is no effective therapy for this disorder, although nitisinone inhibits the enzyme that produces HGA. We performed a study to delineate the natural history of alkaptonuria. METHODS: We evaluated 58 patients with alkaptonuria (age range, 4 to 80 years), using clinical, radiographic, biochemical, and molecular methods. A radiographic scoring system was devised to assess the severity of spinal and joint damage. Two patients were treated with nitisinone for 10 and 9 days, respectively. RESULTS: Life-table analyses showed that joint replacement was performed at a mean age of 55 years and that renal stones developed at 64 years, cardiac-valve involvement at 54 years, and coronary-artery calcification at 59 years. Linear regression analysis indicated that the radiographic score for the severity of disease began increasing after the age of 30 years, with a more rapid increase in men than in women. Twenty-three new HGO mutations were identified. In a 51-year-old woman, urinary HGA excretion fell from 2.9 to 0.13 g per day after a 10-day course of nitisinone (7 days at a dose of 0.7 mg per day and 3 days at 2.8 mg per day). In a 59-year-old woman, urinary HGA fell from 6.4 g to 1.7 g per day after nine days of treatment with nitisinone (0.7 mg per day). Plasma tyrosine levels in these patients rose from approximately 1.1 mg per deciliter (60 micromol per liter) in both to approximately 12.8 mg per deciliter (700 micromol per liter) and 23.6 mg per deciliter (1300 micromol per liter), respectively, with no clinical signs or symptoms. CONCLUSIONS: The reported data on the natural history of alkaptonuria provide a basis for the evaluation of long-term therapies. Although nitisinone can reduce HGA production in humans with homogentisate 1,2-dioxygenase deficiency, the long-term safety and efficacy of this treatment require further evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
THE INCIDENCE OF ALKAPTONURIA : A STUDY IN CHEMICAL INDIVIDUALITY.
Garrod, A. (1902) · The Lancet · doi:10.1016/s0140-6736(01)41972-6 · Cited by 789
Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
LINDSTEDT, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)92685-9 · Cited by 631
Macrae, I. F., & Wright, V (1969) · Annals of the Rheumatic Diseases · doi:10.1136/ard.28.6.584 · Cited by 389
THE NATURE OF THE DEFECT IN TYROSINE METABOLISM IN ALCAPTONURIA
La Du, B. N., Zannoni, V. G., Laster, L., & Seegmiller, J. E. (1958) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)70560-7 · Cited by 354
Choosing measures of health status for individuals in general populations.
Ware, J. E., Brook, R. H., Davies, A. R., & Lohr, K. N. (1981) · American Journal of Public Health · doi:10.2105/ajph.71.6.620 · Cited by 340
The molecular basis of alkaptonuria
Fernández-Cañón, J. M., Granadino, B., De Bernabé, D. B., Renedo, M., Fernández-Ruiz, E., Peñalva, M. A., & De Córdoba, S. R. (1996) · Nature Genetics · doi:10.1038/ng0996-19 · Cited by 329
Biochemical, pathologic and clinical aspects of alcaptonuria, ochronosis and ochronotic arthropathy
O’Brien, W. M., Du, B. N. L., & Bunim, J. J. (1963) · The American Journal of Medicine · doi:10.1016/0002-9343(63)90089-5 · Cited by 310
Normal range of spinal mobility. An objective clinical study.
Moll, J. M., & Wright, V (1971) · Annals of the Rheumatic Diseases · doi:10.1136/ard.30.4.381 · Cited by 267
Cited by
4-Hydroxyphenylpyruvate dioxygenase
Moran, G. R. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.08.015 · Cited by 306
Widespread Use of Toxic Skin Lightening Compounds: Medical and Psychosocial Aspects
Ladizinski, B., Mistry, N., & Kundu, R. V. (2011) · Dermatologic Clinics · doi:10.1016/j.det.2010.08.010 · Cited by 156
Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1
Santra, S., & Baumann, U. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.7.1229 · Cited by 68
Disorders of Tyrosine Metabolism
Chakrapani, A., & Holme, E. (2006) · Inborn Metabolic Diseases · doi:10.1007/978-3-540-28785-8_18 · Cited by 52
Disorders of Tyrosine Metabolism
Chakrapani, A., Gissen, P., & McKiernan, P. (2012) · Inborn Metabolic Diseases · doi:10.1007/978-3-642-15720-2_18 · Cited by 17
Metadata
- Authors
- Phornphutkul, C., Introne, W. J., Perry, M. B., Bernardini, I., Murphey, M. D., Fitzpatrick, D. L., Anderson, P. D., Huizing, M., Anikster, Y., Gerber, L. H., & Gahl, W. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-12-26
- Volume
- 347
- Issue
- 26
- Pages
- 2111-2121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1977056090
- Cited by
- 665
- References
- 24
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Natural History of Alkaptonuria. https://app.cochat.ai/papers/10.1056/nejmoa021736
- The paper
- Phornphutkul, C., Introne, W. J., Perry, M. B., Bernardini, I., Murphey, M. D., Fitzpatrick, D. L., Anderson, P. D., Huizing, M., Anikster, Y., Gerber, L. H., & Gahl, W. A. (2002). Natural History of Alkaptonuria. New England Journal of Medicine. https://doi.org/10.1056/nejmoa021736
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.